These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 21519359

  • 1. Efficacy and harms of nasal calcitonin in improving bone density in young patients with inflammatory bowel disease: a randomized, placebo-controlled, double-blind trial.
    Pappa HM, Saslowsky TM, Filip-Dhima R, DiFabio D, Hassani Lahsinoui H, Akkad A, Grand RJ, Gordon CM.
    Am J Gastroenterol; 2011 Aug; 106(8):1527-43. PubMed ID: 21519359
    [Abstract] [Full Text] [Related]

  • 2. Effect of calcium and vitamin D supplementation on bone mineral density in children with inflammatory bowel disease.
    Benchimol EI, Ward LM, Gallagher JC, Rauch F, Barrowman N, Warren J, Beedle S, Mack DR.
    J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):538-45. PubMed ID: 18030230
    [Abstract] [Full Text] [Related]

  • 3. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
    Soo I, Siffledeen J, Siminoski K, McQueen B, Fedorak RN.
    J Crohns Colitis; 2012 Aug; 6(7):777-86. PubMed ID: 22398088
    [Abstract] [Full Text] [Related]

  • 4. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 5. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS, Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators.
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [Abstract] [Full Text] [Related]

  • 6. Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis.
    Pornpaisalsakul K, Songtaweesin WN, Tepmongkol S, Wongharn P, Kawichai S, Suponsilchai V, Anugulruengkitt S, Puthanakit T, CE-PID - IHRI Adolescent Study Team.
    J Int AIDS Soc; 2020 Oct; 23(10):e25624. PubMed ID: 33040465
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial.
    Binkley N, Bone H, Gilligan JP, Krause DS.
    Osteoporos Int; 2014 Nov; 25(11):2649-56. PubMed ID: 25027109
    [Abstract] [Full Text] [Related]

  • 8. Update: Vitamin D3 and calcium carbonate supplementation for adolescents with HIV to reduce musculoskeletal morbidity and immunopathology (VITALITY trial): study protocol for a randomised placebo-controlled trial.
    Dzavakwa NV, Chisenga M, McHugh G, Filteau S, Gregson CL, Kasonka L, Kranzer K, Mabuda HB, Mujuru H, Redzo N, Rowland-Jones S, Schaible UE, Simms V, Ferrand RA, VITALITY team.
    Trials; 2024 Jul 22; 25(1):499. PubMed ID: 39039558
    [Abstract] [Full Text] [Related]

  • 9. Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.
    Rizzoli R, Sigaud A, Azria M, Herrmann FR.
    Osteoporos Int; 2015 Jan 22; 26(1):383-93. PubMed ID: 25566730
    [Abstract] [Full Text] [Related]

  • 10. Reduced spinal bone mineral density in adolescents of an Ultra-Orthodox Jewish community in Brooklyn.
    Taha W, Chin D, Silverberg AI, Lashiker L, Khateeb N, Anhalt H.
    Pediatrics; 2001 May 22; 107(5):E79. PubMed ID: 11331729
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness and safety of vitamin D in relation to bone health.
    Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V.
    Evid Rep Technol Assess (Full Rep); 2007 Aug 22; (158):1-235. PubMed ID: 18088161
    [Abstract] [Full Text] [Related]

  • 12. Risk Factors of Low Bone Mineral Density in Newly Diagnosed Pediatric Inflammatory Bowel Disease.
    Ahn MB, Yoo IH.
    Nutrients; 2023 Dec 08; 15(24):. PubMed ID: 38140307
    [Abstract] [Full Text] [Related]

  • 13. Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease.
    Bernstein CN, Bector S, Leslie WD.
    Am J Gastroenterol; 2003 Nov 08; 98(11):2468-73. PubMed ID: 14638350
    [Abstract] [Full Text] [Related]

  • 14. Effect of Calcium and Vitamin D Supplementation (Dairy vs. Pharmacological) on Bone Health of Underprivileged Indian Children and Youth with Type-1 Diabetes: A Randomized Controlled Trial.
    Khadilkar A, Oza C, Antani M, Shah N, Lohiya N, Khadilkar V, Bhor S, Kajale N, Gondhalekar K, More C, Katapally TR, Mughal Z, Bhawra J, Padidela R.
    J Clin Densitom; 2024 Nov 08; 27(2):101468. PubMed ID: 38325238
    [Abstract] [Full Text] [Related]

  • 15. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
    Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A.
    Bone; 1995 Oct 08; 17(4):383-90. PubMed ID: 8573412
    [Abstract] [Full Text] [Related]

  • 16. Effect of Low-Magnitude Mechanical Stimuli on Bone Density and Structure in Pediatric Crohn's Disease: A Randomized Placebo-Controlled Trial.
    Leonard MB, Shults J, Long J, Baldassano RN, Brown JK, Hommel K, Zemel BS, Mahboubi S, Howard Whitehead K, Herskovitz R, Lee D, Rausch J, Rubin CT.
    J Bone Miner Res; 2016 Jun 08; 31(6):1177-88. PubMed ID: 26821779
    [Abstract] [Full Text] [Related]

  • 17. Risk factors for low bone mineral density in children and adolescents with inflammatory bowel disease.
    Lopes LH, Sdepanian VL, Szejnfeld VL, de Morais MB, Fagundes-Neto U.
    Dig Dis Sci; 2008 Oct 08; 53(10):2746-53. PubMed ID: 18351466
    [Abstract] [Full Text] [Related]

  • 18. A single dose of intravenous zoledronate prevents glucocorticoid therapy-associated bone loss in acute flare of Crohn's disease, a randomized controlled trial.
    Klaus J, Haenle MM, Schröter C, Adler G, von Boyen G, Reinshagen M, von Tirpitz C.
    Am J Gastroenterol; 2011 Apr 08; 106(4):786-93. PubMed ID: 21386830
    [Abstract] [Full Text] [Related]

  • 19. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.
    Osteoporos Int; 2006 Apr 08; 17(5):716-23. PubMed ID: 16463007
    [Abstract] [Full Text] [Related]

  • 20. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease.
    Sylvester FA, Wyzga N, Hyams JS, Davis PM, Lerer T, Vance K, Hawker G, Griffiths AM.
    Inflamm Bowel Dis; 2007 Jan 08; 13(1):42-50. PubMed ID: 17206638
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.